New FDA Leadership Could Raise The Bar For Drug Approvals
CAPRA former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.
May 9, 2025
Read more →Capricor Therapeutics Announces Completion Of Mid-Cycle Review Meeting With FDA On Deramiocel For The Treatment Of Duchenne Muscular Dystrophy Cardiomyopathy; Remains On Track For PDUFA Target Action Date Of August 31, 2025
CAPRMay 5, 2025
Read more →uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
CAPRApril 17, 2025
Read more →Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
CAPRMarch 20, 2025
Read more →Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $30 Price Target
CAPRMarch 20, 2025
Read more →A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts
CAPRMarch 20, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
CAPRMarch 20, 2025
Read more →Capricor Therapeutics Q4 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $11.10M Beat $5.68M Estimate
CAPRMarch 19, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
CAPRMarch 17, 2025
Read more →Capricor Therapeutics Announces Data From Ongoing HOPE-2 Open Label Extension Clinical Trial
CAPRMarch 17, 2025
Read more →Capricor Accepted By FDA For Deramiocel BLA Filing For DMD Cardiomyopathy, Priority Review Granted, PDUFA Date Set For August 31, 2025; NS Pharma To Commercialize In U.S.
CAPRMarch 10, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
CAPRMarch 4, 2025
Read more →Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
CAPRFDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues.
March 4, 2025
Read more →Market-Moving News for March 4th
CAPRMarch 4, 2025
Read more →Capricor Says FDA Granted Deramiocel BLA Priority Review And Assigned PDUFA Target Action Date Of August 31, 2025
CAPRMarch 4, 2025
Read more →Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By EMA
CAPRNovember 20, 2024
Read more →Jones Trading Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $40
CAPRNovember 18, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
CAPRNovember 14, 2024
Read more →Decoding 12 Analyst Evaluations For Capricor Therapeutics
CAPRNovember 14, 2024
Read more →Cantor Fitzgerald Maintains Overweight on Capricor Therapeutics, Raises Price Target to $30
CAPRNovember 14, 2024
Read more →Oppenheimer Initiates Coverage On Capricor Therapeutics with Outperform Rating, Announces Price Target of $14
CAPRMay 17, 2024
Read more →